Business and Finance

Cambridge BioMarketing brings orphan-drug expertise, and Vynamic brings branding and launch services

Assn. for Accessible Medicines files a federal suit against the state

Fourth annual meeting will occur Oct. 16-17

$325-million cancellation fee to be paid to Rite Aid

Specialty pharmacy accreditation attracts growing number of pharmacies

Lifetime Achievement Award goes to Michael McBride, Upsher-Smith Labs

Novartis, Pfizer and Roche will run neck-and-neck for global leader spot

The southern California region carves out a special place for genomics within biotechnology

Healthcare stakeholders ruminate on the effects of MACRA’s alternative payment models

Survey of the global business consulting market finds double-digit growth for pharma

Taking on the breadth of challenges in contract development and manufacturing, globally

Deal brings a leading CDMO under Thermo Fisher’s expansive life-sciences wings

Combined company will have revenues of $3.2 billion and a market cap of $7.4 billion

Trade association is now big companies with big R&D spending

Takes reins with prior experience at both FDA and HHS

Latest QuintilesIMS report sees 5.8% growth in 2016; more emphasis on ‘net-price’ spending

EMD Serono Specialty Digest finds they struggle over 'ensuring clinically appropriate use'

Acquisition of PharmaMetrics adds payer analytics to Integrichain’s channel, pharmacy intelligence

‘Why fund your competitors?’ asks the company, in a pitch to independents served by the Big 3 wholesalers

$6.1-billion acquisition of Medtronic assets for patient care consumables

Reimbursement is just one of the issues facing biosimilar commercialization in the US

GPhA rebrands and aligns more closely with biosimilars

PhRMA is critical of basing coinsurance or deductibles on drugs’ list prices

5.4-million-member BCBS Federal Employee Program (FEP) is moving

Scott Gottlieb, a former FDA and CMS executive, brings an experienced hand

Initial plans include having a ‘seat at the table’ in PBM formulary discussions

Rare-disease drug also garnered a valuable pediatric review voucher

GPhA rebrands and aligns more closely with biosimilars